Monopar Therapeutics' (MNPR) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a research report released on Wednesday, MarketBeat reports. The firm currently has a $76.00 target price on the stock.

Separately, HC Wainwright upped their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, January 22nd.

Monopar Therapeutics Trading Down 10.6 %

MNPR traded down $4.74 during trading on Wednesday, reaching $40.00. 59,486 shares of the company were exchanged, compared to its average volume of 361,132. The stock has a market cap of $244.08 million, a P/E ratio of -20.30 and a beta of 1.18. The firm has a 50 day moving average of $37.16 and a 200 day moving average of $22.81. Monopar Therapeutics has a 52 week low of $1.72 and a 52 week high of $54.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $3,694,000. Janus Henderson Group PLC bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $23,435,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $11,247,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $13,182,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $2,861,000. Institutional investors own 1.83% of the company's stock.

Remove Ads

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.